Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiuyuan Genetic Engineering Files for Hong Kong IPO

publication date: Jul 26, 2024

Hangzhou Jiuyuan Genetic Engineering has filed for an IPO on the Hong Kong Exchange to develop its portfolio of biopharmaceutical products and medical devices. Founded in 1993, the company has two major products: a drug-device combination product, Guyoudao, the first product containing bone repair material with rhBMP-2 that is approved for China use, and the first semaglutide biosimilar in China to have filed an NDA. Semaglutide is a Novo Nordisk GLP-1 product known as Wegovy for weight loss and Ozempic for type 2 diabetes. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here